U.S. President Donald Trump has announced a 100 % tariff on imports of branded drugs beginning in October, targeting the European Union, which is the main supplier of patented medicines to the United States. The tariff is intended to encourage manufacturers to relocate production to America. It will not apply to companies already investing in U.S. manufacturing, and exemptions are granted for plants that are under construction. Generic medicines, largely imported from India, are exempt from the levy.
The measure is expected to hit Europe hardest, as countries such as Ireland, Germany, Switzerland and Belgium dominate the supply of branded drugs to the U.S. In April, Trump criticized the EU’s trade practices, claiming the bloc pressures pharmaceutical companies to keep prices low in Europe while refusing to share the costs of research and development. In response, major firms—including Merck & Co., AstraZeneca and Johnson & Johnson—have announced billions of dollars in new U.S. manufacturing projects.
However, 32 pharmaceutical companies have warned that the tariffs could divert more than €100 billion in investment away from Europe over the next few years. Their CEOs have urged the European Commission to overhaul pricing rules, strengthen patent protections and streamline regulation in order to keep the continent competitive.
Trump’s decision to impose tariffs on branded drugs carries significant implications for the pharmaceutical industry and international trade. As the EU is the primary source of patented medicines for the United States, the tariff is likely to have a substantial impact on both the industry and the global economy, underscoring the ongoing trade tensions between the two regions. The effects of the tariff will be closely watched, with its influence on pharmaceutical investment and cross‑border trade expected to be considerable.
Comments are closed for this story.